Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Endocrine 2Sarcoma 1Other neoplasm 1Other hematologic neoplasm 1NET 1Lymphoid 1Genitourinary 1Dermatologic 1CNS 1Breast 1

Conditions

Advanced Malignant Neoplasm 1

Interventions

Cyclophosphamide 13Peripheral Blood Stem Cell Transplantation 9Biopsy 9fludarabine phosphate 8Busulfan 8Whole-Body Irradiation 7Surveys and Questionnaires 6Mycophenolic Acid 6Educational Status 6Early Intervention, Educational 6Carboplatin 6fludarabine 5Tacrolimus 5Paclitaxel 5Methotrexate 5Methods 5Melphalan 5Epoetin Alfa 5Decitabine 5Cyclosporine 5Colposcopy 5Cisplatin 5Celecoxib 5Antilymphocyte Serum 5Aminolevulinic Acid 5Sulindac 4Selenium 4Radiotherapy 4Patient Reported Outcome Measures 4Magnetic Resonance Spectroscopy 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Acetates × Other neoplasm × Clear all
NCT01867294 2020-01-09

Spironolactone in Preventing Rash in Patients With Advanced Cancer Receiving Panitumumab and Cetuximab

Academic and Community Cancer Research United

Phase 2 Completed
19 enrolled 9 charts
Other neoplasm

Advanced Malignant Neoplasm

Data powered by HemOnc (CC BY 4.0) Colophon âš¡